The Korea Bizwire18h
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...
GlobalData on MSN19h
MSD secures worldwide license for LaNova’s LM-299
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
PipelineReview.com23h
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...